Dr. Darrell Tan, an infectious disease physician and Canadian HIV prevention leader, discusses the groundbreaking drug lenacapavir, which promises a revolutionary six-month injectable option for HIV prevention. He emphasizes the need for Canadian doctors to advocate for equitable access to this treatment. Dr. Catherine Martin, a senior researcher from Johannesburg, highlights the critical real-world testing of lenacapavir in southern Africa, particularly for young women, and addresses the challenges of implementation, including cost and regulatory hurdles.
